Nasdaq gnlx.

WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...WebWESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...WebWESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on ...WESTLAKE VILLAGE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication in Frontiers in ...Genelux (NASDAQ:GNLX) PT Lowered to $30.00 americanbankingnews.com - November 25 at 3:58 AM: Genelux VP Sold $191K In Company Stock benzinga.com - November 23 at 12:58 PM: Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25% finance.yahoo.com - November 17 at 8:49 AM

May 15, 2023 · WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 ...

WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 ...About After Hours Quotes. Nasdaq provides market information on after hours trading daily from 4:15 p.m. ET to 3:30 p.m. ET on the following day. $202.77 1.43%. Bed Bath & Beyond Inc. Common Stock.

WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad ...WebNASDAQ GNLX opened at $11.10 on Monday. Genelux Co. has a twelve month low of $5.35 and a twelve month high of $40.98. Genelux Co. has a twelve month low of $5.35 and a twelve month high of $40.98.The average price predicted for Genelux Corp (GNLX) by analysts is $36.00, which is $22.03 above the current market price. The public float for GNLX is 18.34M, and at present, short sellers hold a 4.76% of that float. On November 07, 2023, the average trading volume of GNLX was 223.78K shares. Top 5 AI Stocks to Buy for 2023.GNLX Genelux Corporation Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian CancerAbout Pre-Market Quotes. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Bed Bath & Beyond Inc. Common Stock. 1.74%.

View live Genelux Corporation chart to track its stock's price action. Find market predictions, GNLX financials and market news.

Gold -0.10(-0.00%) Genelux Corporation (GNLX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 10.38 -0.34 (-3.17%) At close: 04:00PM EST 10.64 +0.26 (+2.50%) After hours:...

WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...See the latest Genelux Corp stock price (GNLX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Genelux Corporation Common Stock (GNLX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Genelux (NASDAQ:GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer. The company is currently ...WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug ...

Nov 24, 2023 · Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian ... Find the latest Earnings Report Date for Genelux Corporation Common Stock (GNLX) at Nasdaq.com. 01/26/2023. $6.15. Back to GNLX Overview. Nasdaq Official Closing Price (NOCP)" is a process for identifying the Nasdaq market-specific closing price for Nasdaq-listed issues. Data provided by ...Genelux Corporation Common Stock (GNLX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets. WESTLAKE VILLAGE, Calif. , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023 , the Company’s Board of Directors (the “Board”) granted inducement awards consisting of non-qualified stock September 14, …Web

Genelux (NASDAQ:GNLX – Get Free Report) had its price target reduced by equities researchers at Benchmark from $38.00 to $30.00 in a research note issued on Friday, Benzinga reports. The firm presently has a “speculative buy” rating on the stock. Benchmark’s price target points to a potential upside of 170.27% from the company’s …WebYong Yu, VP at Genelux GNLX, reported a large insider sell on November 22, according to a new SEC filing. Genelux shares are trading up 7.9% at $11.2 at the time of this writing on Thursday ...

Genelux Corporation Common Stock (GNLX) Nasdaq Listed; Nasdaq 100; Data is currently not available. Bid: Ask: Volume: 0. ... anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...Find the latest dividend history for Global Net Lease, Inc. Common Stock (GNL) at Nasdaq.com.Genelux Co. (NASDAQ:GNLX – Free Report) – Brookline Capital Management reduced their FY2023 earnings per share (EPS) estimates for shares of Genelux in a research note issued on Tuesday, November 14th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($1.03) per share for the year, down from their […]Companies that could price their IPOs and start trading include Genelux (NASDAQ:GNLX), Elate Group , MorningStar Partners , and Syla Technologies . Intel earnings ...WebNVIDIA Corporation Common Stock. $435.70 -0.93 -0.21%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ... Find the latest historical data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.Find the latest Earnings Report Date for Genelux Corporation Common Stock (GNLX) at Nasdaq.com. Top 25 Mutual Funds Where Should I Retire? Top 25 ETFs MarketWatch Picks Close Search Overlay $749.20K Ex-Dividend Date % of Float Shorted Oct. 27, 2023 at 1:30 …View real-time GNLX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...WebClinical-stage immuno-oncology company, Genelux (NASDAQ:GNLX) said that Lourie S. Zak will join the company as CFO, effective August 28, 2023.Ms. Zak will join Genelux with an extensive background ...

Late clinical-stage immuno-oncology company, Genelux (NASDAQ:GNLX) announced a private placement of 1.67M shares at a price of $20 per share, for gross proceeds of approximately $33M.Proceeds from ...

Genelux Corporation Common Stock (GNLX) Nasdaq Listed; Nasdaq 100; Data is currently not available. Bid: Ask: Volume: 0. ... anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...

Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have set an average share price target of $34.33. The firm's second quarter results saw it outline $27.1 million cash in hand, which, along with other ...Genelux is a publicly-traded biopharmaceutical company (Nasdaq: GNLX). It currently is conducting a Phase 3 registrational trial in resistant/refractory ...10% least volatile stocks in US Market. 2.9%. Stable Share Price: GNLX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week. Volatility Over Time: GNLX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.Based on analysts offering 12 month price targets for GNLX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Sign in to your ...Genelux (NASDAQ:GNLX) opened up its shares for public trading for the first time since it filed for IPO in June 2022. The company agreed to initially offer 2.50 million shares to the public at $6.00 per share. ... For its IPO, GNLX agreed to offer 2.50 million shares at a price of $6.00 per share, with an insider lock-up period of 180 days ...WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...The latest price target for Genelux ( NASDAQ: GNLX) was reported by Maxim Group on Tuesday, September 12, 2023. The analyst firm set a price target for 40.00 expecting GNLX to rise to within 12 ...Find the latest Financials data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.WebGenelux (NASDAQ:GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer. The company is currently ...

20. 11. 2023 ...May 25, 2023 · WESTLAKE VILLAGE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication of positive topline ... Shares of Genelux Corporation (NASDAQ:GNLX) got a boost, shooting 24% to $36.67. Sea Limited (NYSE:SE) shares were also up, gaining 16% to $76.09 after the company reported better-than-expected Q4 ...Instagram:https://instagram. riggi mansion auctionecopetrol sa stockbuying stocks directlywhich investment company is the best According to the issued ratings of 3 analysts in the last year, the consensus rating for Genelux stock is Buy based on the current 3 buy ratings for GNLX. The average twelve-month price prediction for Genelux is $25.00 with a high price target of $40.00 and a low price target of $10.00. Learn more on GNLX's analyst rating history. best broker to short stocksperrigo stocks Genelux Co. (NASDAQ:GNLX – Free Report) – Brookline Capital Management reduced their FY2023 earnings per share (EPS) estimates for shares of Genelux in a research note issued on Tuesday, November 14th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($1.03) per share for the year, down from their […]Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ... where to buy polygon Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25%. Key Insights Significant control over Genelux by retail investors …01/26/2023. $6.15. Back to GNLX Overview. Nasdaq Official Closing Price (NOCP)" is a process for identifying the Nasdaq market-specific closing price for Nasdaq-listed issues. Data provided by ...Genelux Corp (NASDAQ:GNLX) 14.07 Delayed Data As of 3:59pm ET -0.37 / -2.56% Today’s Change 5.35 Today ||| 52-Week Range 40.98 -- Year-to-Date Quote Profile News Charts Forecasts Financials...